Summary: The Centers for Medicare & Medicaid Services modified its FDG PET scan coverage policy for lung cancer, retiring the standalone policy and replacing it with Section 220.6.17, effective May 15, 2026. Here's what billing teams need to do before that date.
This change affects FDG PET scan billing across oncology, pulmonology, and thoracic surgery practices that bill Medicare. The Centers for Medicare & Medicaid Services is consolidating its PET imaging coverage policies under a unified framework — a pattern CMS has followed with other imaging NCDs over the past several years. This policy does not list specific CPT or HCPCS codes in the available policy data, so your team will need to reference Section 220.6.17 directly for code-level guidance.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | FDG PET for Lung Cancer — Retired, Replaced by Section 220.6.17 |
| Policy Code | N/A |
| Change Type | Modified (Retirement / Consolidation) |
| Effective Date | 2026-05-15 |
| Impact Level | High |
| Specialties Affected | Oncology, Pulmonology, Thoracic Surgery, Nuclear Medicine, Radiology |
| Key Action | Update your payer policy references and billing guidelines to Section 220.6.17 before May 15, 2026 |
CMS FDG PET Lung Cancer Coverage Criteria and Medical Necessity Requirements 2026
The real issue here is structural. CMS isn't changing what it covers — it's changing where the rules live. The standalone FDG PET for lung cancer coverage policy is gone. Section 220.6.17 is now the authoritative source for medical necessity criteria governing FDG PET scans in lung cancer.
That distinction matters for your billing team. If your charge capture workflows, prior authorization checklists, or internal billing guidelines still reference the old standalone policy, they're now pointing to a retired document. Claims built on outdated policy citations won't automatically fail — but if a claim is audited or disputed, your documentation trail needs to line up with the current coverage policy.
FDG PET scans have long been a Medicare coverage area with specific medical necessity requirements. CMS has historically required that FDG PET for lung cancer be used for one or more of three purposes: diagnosis, staging, or restaging. Coverage has also extended to monitoring treatment response in certain clinical scenarios. Section 220.6.17 consolidates these criteria into a single, unified policy that governs all oncologic PET imaging under Medicare — not just lung cancer.
This consolidation follows the same pattern CMS used when it unified cardiac imaging NCDs several years ago. The clinical criteria don't disappear. They migrate. Your job is to find them in the new home and update your documentation accordingly before May 15, 2026.
If your practice has a high volume of FDG PET claims for lung cancer patients, talk to your compliance officer now. A policy retirement and consolidation is a clean trigger for an internal audit of your documentation templates and prior authorization workflows.
CMS FDG PET for Lung Cancer Exclusions and Non-Covered Indications
CMS has historically drawn clear lines on what FDG PET does not cover for lung cancer under Medicare. Screening use — ordering a PET scan on an asymptomatic patient without a prior diagnosis or clinical suspicion — has never met medical necessity under this coverage policy framework.
Routine follow-up imaging that isn't tied to a documented clinical question (restaging, treatment response, suspected recurrence) has also faced claim denial risk. The consolidation into Section 220.6.17 doesn't soften those exclusions. If anything, a unified policy framework makes it easier for MACs to apply consistent denial logic across all oncologic PET claims.
The available policy data does not list specific excluded indications with attached codes. Pull Section 220.6.17 directly from the CMS NCD Manual to get the current exclusion language verbatim. Don't rely on summaries — use the source document for your compliance templates.
Coverage Indications at a Glance
The policy data available for this retired policy does not include a granular indication-by-indication breakdown with attached CPT or ICD-10 codes. The table below reflects what CMS has historically covered under the FDG PET for lung cancer framework, based on the NCD framework that Section 220.6.17 now governs. Verify each indication directly in Section 220.6.17 before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Initial diagnosis / characterization of pulmonary nodule | Covered (historically) | See Section 220.6.17 | Medical necessity documentation required |
| Initial staging of confirmed lung cancer | Covered (historically) | See Section 220.6.17 | Must document staging clinical question |
| Restaging after treatment | Covered (historically) | See Section 220.6.17 | Requires documented clinical rationale |
| Treatment response monitoring | Covered (historically) | See Section 220.6.17 | Coverage dependent on clinical criteria |
| Screening in asymptomatic patients | Not Covered | N/A | Has not met medical necessity under CMS policy |
| Routine surveillance without clinical indication | Not Covered / Claim Denial Risk | N/A | Document clinical question clearly to avoid denial |
CMS FDG PET Lung Cancer Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull Section 220.6.17 from the CMS NCD Manual now. Don't wait until May 14. The retired policy is gone. Section 220.6.17 is the live document. Your billing team needs to read it, not just know it exists. |
| 2 | Update all internal billing guidelines and charge capture templates before May 15, 2026. Anywhere your documentation references the old standalone FDG PET for lung cancer policy, replace it with a reference to Section 220.6.17. This includes charge capture workflows, coder reference sheets, and payer policy binders. |
| 3 | Audit your prior authorization templates. If your prior auth requests for FDG PET scans cite policy language from the retired document, update them. A prior authorization request that cites a retired policy can raise flags with MAC reviewers even if the underlying clinical facts support coverage. |
| 4 | Check your MAC's local coverage determination for any supplemental rules. Section 220.6.17 sets the national floor. Your Medicare Administrative Contractor may have an LCD that adds requirements on top of the NCD. Contact your MAC directly or check their website to confirm whether any local coverage determination applies to FDG PET for lung cancer in your region. |
| 5 | Review open claims and appeals that reference the retired policy. Any claim currently in dispute or under appeal that cites the old standalone policy needs updated documentation. Work with your billing consultant or compliance officer to determine whether resubmission or amended documentation is appropriate. |
| 6 | Brief your medical directors and ordering providers. The medical necessity documentation they generate supports your claims. If their clinical templates still reference outdated coverage criteria, your claims inherit that risk. Give them a one-page summary of what changed and what Section 220.6.17 requires before the effective date. |
| 7 | If your practice bills high volumes of FDG PET for lung cancer, loop in your compliance officer before May 15. A policy consolidation is a natural audit trigger. Getting ahead of it internally is cheaper than responding to a post-payment review. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for FDG PET Lung Cancer Under This Policy Change
The available policy data for this change does not list specific CPT, HCPCS, or ICD-10 codes. Do not rely on this post for code-level guidance on FDG PET scan billing.
Where to Find the Actual Codes
Go directly to Section 220.6.17 of the CMS National Coverage Determinations Manual. That document is now the authoritative source for which codes CMS covers under the FDG PET framework for oncologic indications, including lung cancer.
Your MAC may also publish a companion LCD with additional code-level guidance. Check both sources before updating your charge capture.
Why This Matters for Reimbursement
FDG PET scans carry significant reimbursement value. Billing the wrong code, or billing without documentation that maps to Section 220.6.17's criteria, exposes your practice to claim denial and potential recoupment. This is not a policy change you can address by updating a single field in your billing system — it requires a documentation and workflow review.
If you're unsure which CPT codes your practice uses for FDG PET scans, run a utilization report filtered by your nuclear medicine or radiology charges from the past 12 months. That report will show you your actual code mix. Then map each code to Section 220.6.17 to confirm continued coverage.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.